Ingram Micro To Replace Pacira Biosciences In the S&P SmallCap 600 Effective Prior To The Opening Of Trading On Tuesday, November 17
Pacira BioSciences Withdraws 2026 Guidance Pending Proposed Merger With Viatris
Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
Viatris Subsidiary Peach Purchaser Sub Commences Tender Offer To Acquire Pacira Biosciences For $36.50/Shr
Pacira BioSciences (PCRX) Stock Gets Fair Value Boost After Viatris Deal Framing
Pacira Biosciences' Acquisition by Viatris Unlikely to See Superior Bid, RBC Says
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
Truist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5
HC Wainwright & Co. Downgrades Pacira BioSciences to Neutral, Lowers Price Target to $36.5
Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly
Viatris to acquire Pacira BioSciences for $1.65 billion
Why Is Viatris (VTRS) Expanding Its Non Opioid Pain Portfolio Now?
HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
Viatris makes foray into non-opioid pain space on $1.65bn Pacira buyout
Viatris Agrees to Acquire Pacira BioSciences in $1.65 Billion Deal
Jefferies Downgrades Pacira BioSciences to Hold, Announces $36 Price Target
Viatris boosts pain drug portfolio with $1.7B buyout of Pacira
Viatris Agrees to Acquire Pacira BioSciences for $1.65 Billion in Non-Opioid Pain Therapy Expansion
Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.